Otsuka Pharmaceutical Company, Ltd. has been selected to receive the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2019 Spring Clinical Meetings in Boston. In April 2018, Otsuka’s JYNARQUETM (tolvaptan) was approved by the U.S. Food and Drug Administration (FDA) as the first treatment to slow kidney function decline in adults at risk of rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD).
ADPKD is diagnosed in about 140,000 people in the U.S., and impacts families across multiple generations, since a parent with ADPKD has a 50 percent chance of passing the disease to their children. ADPKD is a genetic disease with consequences that can lead to dialysis or kidney transplantation. It is a progressively debilitating and often painful disorder in which fluid-filled cysts develop in the kidneys over time. These cysts enlarge the kidneys and impair their ability to function normally, leading to kidney failure in most patients. Otsuka is being recognized for improving the lives of people as a result of the introduction of tolvaptan.
The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease. For more information about NKF visit www.kidney.org.
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: Otsuka-people creating new products for better health worldwide. Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.